drugset / Trial / NCT04649541
Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts
Phase 1
Completed
69 enrolled
MicuRx
Biomedical Advanced Research and Development Authority · collabWellcome Trust · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase 1 study is designed to assess the safety and tolerability of single and multiple intravenous (IV) doses of MRX-8, to assess the pharmacokinetics of MRX-8 and its primary metabolite following single and multiple IV doses, and to measure the elimination of MRX-8 and its metabolite in urine.
Timeline
- Start
- 2020-11-29
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MRX-8 | Unknown | — | Intravenous |
Indications
No indication recorded.